Fundamental Analysis of LEAP THERAPEUTICS INC(NASDAQ:LPTX) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to LPTX. LPTX was compared to 587 industry peers in the Biotechnology industry. The financial health of LPTX is average, but there are quite some concerns on its profitability. LPTX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LPTX has reported negative net income.

LPTX had a negative operating cash flow in the past year.

In the past 5 years LPTX always reported negative net income.

LPTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of LPTX (-92.08%) is worse than 81.71% of its industry peers.

LPTX's Return On Equity of -112.67% is on the low side compared to the rest of the industry. LPTX is outperformed by 63.59% of its industry peers.

		Industry Rank	Sector Rank
ROA	-92.08%
ROE	-112.67%
ROIC	N/A

ROA(3y)-74.59%

ROA(5y)-148.47%

ROE(3y)-88.56%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LPTX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for LPTX has been increased compared to 1 year ago.

Compared to 5 years ago, LPTX has more shares outstanding

LPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -6.70, we must say that LPTX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -6.70, LPTX is not doing good in the industry: 62.73% of the companies in the same industry are doing better.

LPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.7

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

LPTX has a Current Ratio of 5.38. This indicates that LPTX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 5.38, LPTX is in line with its industry, outperforming 59.49% of the companies in the same industry.

LPTX has a Quick Ratio of 5.38. This indicates that LPTX is financially healthy and has no problem in meeting its short term obligations.

LPTX's Quick ratio of 5.38 is in line compared to the rest of the industry. LPTX outperforms 59.66% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.38
Quick Ratio	5.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LPTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.86%, which is quite impressive.

EPS 1Y (TTM)65.86%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q84.06%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

LPTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.43% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y54.77%

EPS Next 2Y26.77%

EPS Next 3Y17.13%

EPS Next 5Y13.43%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LPTX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LPTX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as LPTX's earnings are expected to grow with 17.13% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.77%

EPS Next 3Y17.13%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LPTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LEAP THERAPEUTICS INC

NASDAQ:LPTX (5/17/2024, 7:11:15 PM)

After market: 2.7 +0.07 (+2.66%)

2.63

-0.11 (-4.01%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap100.62M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-92.08%
ROE	-112.67%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.38
Quick Ratio	5.38
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)65.86%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y54.77%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

LEAP THERAPEUTICS INC (LPTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens